Other innovations
If your innovation doesn’t fit any of the active categories then this is the place to submit your innovation for feedback and the opportunity for wider adoption across the region.

Ideas (Publish, Detailed Submission)

Innovation 'Elevator Pitch':
Incredible amounts of expensive drugs are thrown away by pharmaceuticals companies, health trusts & GP surgeries due to refrigeration problems. Everyware technology enables remote data monitoring & intervention for pharmaceutical & food storage
Overview of Innovation:
The problem. Correct handling and storage of drugs and medicines is critical in ensuring that they remain functional and safe to use. Regular monitoring and data capture highlights trends and issues not evident from manual record keeping. Over weekends and during holiday periods readings may not be recorded. Failure of a refrigerator or break in power supply could render contents unusable or remain undetected
 
EveryWare has developed an intelligent software platform with smart sensors, integrated and modular, in conjunction with clinicians to tackle this major problem. Local devices monitor a range of parameters, including ambient temperature, pressure and humidity; together with refrigeration temperatures at different levels within each unit
 
Local and remote alerts can be triggered when your own defined rules are breached. Alerts may be visual and audible in a monitored location with users receiving direct notifications via email, SMS and other channels. Data is visualized and accessible on computers, tablets and smartphones
 
Testimonial
Clinical bodies and Trusts’ guidelines require regular monitoring of critical storage temperatures. Legislation requires that records are kept and this is often a manual task with readings taken at up to 24 hour intervals
 
Successful trials yielded a wealth of information for pharmacy staff to gain immediate, real time insight into how efficient their refrigerators are and how ambient conditions and working practices affect them. Clinicians benefit from the reduced workload and the availability of high resolution data proves compliance with healthcare guidelines 24/7

Differences between types of refrigerator become evident. Recovery time following prolonged periods of access can expose the contents to raised temperatures for longer; trend data clearly demonstrates the effects of daily routines and identifies opportunities for training that will improve the safe storage and dispensing of critical medicines
 
EveryWare’s unique modular system means that the unit cost of the sensors is low. All other costs are capped, so no need to worry about data rates and variable costs. Annual cost of the system is a fraction of the cost of the assets or processes being monitored. System is designed from the ground up to be completely user-configurable to suit local and business requirements. Security is paramount; all cloud systems and data are network-isolated, multiple-passkey protected with encrypted communications.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Compliant drug storage
There is a legislative requirement to store critical medicines within specified parameters. Moreover, it is imperative that safe storage can be demonstrated and that only safe products are used.
 
Equally, any fault or disruption to the storage infrastructure doesn’t automatically render the products beyond safe use. Smart monitoring, reporting and validation afford peace of mind. Efficacy of the drugs can be evidenced and detect abnormal patterns of behaviour or access issues e.g. refrigerator door left open.
 
Broad clinical guidelines indicate that regular, period monitoring by technicians will suffice; often once every 24 hours and often not during weekends and holiday periods.
 
There are several risks with this approach that can render expensive drugs ineffective and worse still, fail to deliver the anticipated results. A power outage in the early hours or over a weekend may be masked by a reinstatement long before working hours. The damage may already be done if excessive temperatures have been realised.
 
The solution is to introduce smart monitoring with remote data logging and alerts. Continuous, electronic monitoring not only captures specific events 24/7 and raise alarms but provides valuable trend data. Battery backup will buffer mains failure without disruption to the monitoring or connectivity. Real time monitoring has clearly shown systematic issues occur out of working hours and variations within specific refrigerated facilities. Clinical practices will also affect the storage conditions; a feature that is evident from trend data. The effects of prolonged loading and unloading with the refrigerator open shows the impact upon refrigeration temperatures and the extended recovery time to achieve safe storage temperatures when eventually closed. Access to the refrigerators out of prescribed hours may also raise an alert if there is a security concern.
 
EveryWare has installed local monitoring systems in hospitals and clinical environments that are capable of tracking a range of critical conditions. Not just in refrigeration units but ambient conditions in key locations may be monitored through a common network. Within treatment, theatre, storage or living areas the network of wireless devices can track temperature, relative humidity and pressure along with other factors such as controlled access and refrigeration performance.
 
In homes EveryWare could be used with ambient and movement sensors to detect risk of hypothermia or falls.
 
Initial Review Rating
4.60 (2 ratings)
Benefit to WM population:
Overall benefits summary
Installations of the system have already demonstrated potential savings in recent trials.
  • Money saved by GP surgeries and health trusts through proper refrigeration of medicines
  • Money saved by pharmaceuticals companies through proper refrigeration 
  • Money saved by pharmaceuticals companies by not having to pre-emptively over-produce product to compensate for GP and trust wastage
  • Quality of patient care increases as a result of cost savings throughout the medicine supply chain
  • Meets strict legislative requirements ((strict environmental monitoring protocols are now required by CQC. Failure to comply requires drugs be destroyed at very high cost).
  • Modular (easy to add on additional ambient sensors, movements detectors etc)
  • Quick to install and upgrade
  • Predictive analytics software enables custom ‘rules based’ alerts to be created easily
  • Monitor multiple installations and multiple sensors from a single location (Dashboard)
     
Quality control
  • Constant monitoring of refrigeration and the ability to react instantly minimises the amount of wastage caused by medicine being spoiled by high temperatures. The unique modular design enables additional sensors to be quickly integrated. Predictive analytics software enables custom ‘rules based’ alerts and monitoring protocols to be easily created and monitored.
Legislation
  • The easy monitoring of temperatures makes it much easier to comply with the strict legislation imposed by health bodies such as the MHRA and CQC.
     
GP Surgeries
  • Surgeries and trusts are able to monitor the temperature of their drugs in the refrigerator and react instantly should parameters be broken.
     
Patient care
  • The cost savings made by reducing wastage can be channelled back into the healthcare system, improving overall patient care.
For more information see: http://www.everyware.uk.com/products/21st-century-drug-monitoring
Current and planned activity: 
Current Activity
Successful trials have been conducted with SWFT Clinical Services Ltd (a subsidiary of the South Warwickshire NHS Foundation Trust) which yielded a wealth of information for pharmacy staff to gain immediate, real time insight into how efficient their refrigerators are and how ambient conditions and working practices affect them.
 
Positive actions were taken to improve the effectiveness and avoid potential problems that might have occurred. Clinicians benefit from the reduced workload and the availability of high resolution data proves compliance with healthcare guidelines 24/7.
 
We have recently entered discussions with GP practice in Norfolk in response to CQC’s strict environmental monitoring requirement for drug storage.

Planned Activity
  • We would welcome NHS input in our systems design and further development
  • We wish to increase awareness within GP and CCGs
  • We are seeking additional trial sites
What is the intellectual property status of your innovation?:
All IP resides with the company
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Nigel Maris 18/10/2016 - 10:42 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Tipsim® is a completely new product producing long lasting improvements in sensorimotor abilities of the hand in rehabilitation after brain damage, such as stroke, craniocerebral trauma or other neuro diseases e.g. Complex Regional Pain Syndrome.
Overview of Innovation:
Tip-stimulation with Tipstim® facilitates long-lasting therapy procedures. By sensory stimulation of the finger tips, Tipstim® drives plasticity processes in cerebral areas involved in the activation of the hand and fingers. Specially designed stimulation patterns – developed over many years of research & trials at the Institute for Neuroinformatics at the Ruhr University Bochum – are generated by a small, portable electronic pulse generator and applied directly to the finger tips via a completely new and highly-sophisticated therapy glove. The Tipstim glove® is the first product of its kind to utilise a new advanced medically approved conductive and biocompatible textile.
 
The therapy is completely painless, without side-effects and very easy to apply. The patient simply pulls over the glove, connects it to the pulse generator and starts the therapy session once a day for 1 hour. The therapy does not demand any special attention from the patient. Due to the small size of the pulse generator, the therapy can easily be integrated into everyday life and home. In principle, therapy can be applied everywhere, even when out walking.


 The proven efficiency of Tipstim® results from stimulation pattern specially designed for most effective enforcement of neuroplasticity processes. Clinical studies show that these special patterns produce cerebral changes which lead to persistent improvement of a patient’s sensorimotor abilities. This especially true with sensory and proprioceptive deficits which have shown a greater recovery than with standard rehabilitation therapy alone
 
Studies have shown that sensory stimulation drives plastic processes in the brain areas activated by the stimulation. This induces reorganisation in and around those brain areas that became dysfunctional by stroke or other brain injuries. This reorganization facilitates reactivation of cortical tissue that has preserved some functionality. The resulting remodelling of cortical circuits then mediates functional recovery.
 
Tipstim® is a clinically tested and CE approved product. The efficacy & safety of Tipstim® therapy has been proven in rigorous clinical trials.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Person centred care
Benefit to NHS:
Stroke is the UK’s third biggest killer.
 
First-time incidence of stroke occurs almost 17 million times a year worldwide; one every two seconds. Stroke is one of the largest causes of disability – half of all stroke survivors have a disability.
 
In the UK there are 152,000 recorded incidences of stroke a year and currently over 1.2 million stroke survivors. The economic costs of stroke in the UK from a societal perspective totals around £9 billion a year (Source: State of the Nation Stroke statistics - January 2016). The average cost of care (acute & rehabilitation) per stroke patient is currently £23,315 (National Audit Office. Progress in improving stroke care..., (February 2010). NAO Report (HC 291 2009-2010))
 
Over a third of stroke survivors in the UK are dependent on others.
 
Tipstim® is a completely new product to improve sensorimotor abilities of the hand in rehabilitation after brain damage, such as stroke, craniocerebral trauma and other neurological diseases such as Complex Regional Pain Syndrome.
 
Tipstim® comprises a small, battery powered electronic pulse generator unit and a close fitting glove that delivers the neurostimulation at the finger tips. Due to the compact size of the pulse generator, the therapy can easily be integrated into everyday life. In principle, therapy can be delivered everywhere, even during walking or when reading or watching television.
 
Clinical trials have demonstrated that the stimulation provided by Tipstim®  demonstrates a persistant reactivation of affected brain areas responsible to sensory and motor control of the hand and fingers. Moreover, balancing processes in adjacent non-affected brain areas are promoted.
The result is a substantially improved sense of touch as well as an improved mobility of the concerned hand.
 
The sensory & functional improvements resulting from Tipstim® neurostimulation have been demonstrated to last longer than for traditional therapy alone.
 
The Tipstim® is self contained and can easily be used by the patient in their own home. This reduces the frequency of hospital / clinic visits, frees up therapist time and would enable more patients to be treated than is currently possible.
 
Furthermore, the sensory and functional improvements resulting from the Tipstim® therapy will increase the patient’s ability to carry out task of daily living and will therefore increase their independence, thus reducing the need for additional care and support – with resultant manpower and monetary savings.
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
The West Midlands has the highest mortality for stroke in England in people over 65.
 
The region’s ethnic diversity and socioeconomic status also reflects in a higher than average incidence of strokes as people of black and South Asian origin are at double the risk of stroke as are those living in the most economically deprived areas of the UK (West Midlands has 28.1% of its population in the most deprived national quintile)
 
These statistics demonstrate that the demand for stroke rehabilitation services will be higher than the national average and therefore the opportunity to make a significant impact will be greater for therapies such as Tipstim®.
 
The region also has the lowest percentage of patients returning to their usual place of residence, and this is statistically significantly lower than the England average. Improved  independence and post stroke rehabilitation would help to address this and enable people to return to their own homes and live independently.
Current and planned activity: 
We are currently undertaking a pilot multicentre clinical trial of Tipstim® at the Countess of Chester NHS Foundation Trust, Chester.
We would welcome the opportunity to engage with the West Midland’s Stroke rehabilitation communities to raise awareness of our Tipstim®.
In addition, we wish to explore support for business model development and delivery strategies for NHS adoption and or private procurement.

We are also very interested in conducting a cost benefits analysis health economics study of therapeutic intervention with Tipstim®.
What is the intellectual property status of your innovation?:
Tipstim® is protected via granted patents and registered design rights held by the parent company.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Read more
Hide details
Bharat Vadukul 21/09/2016 - 14:15 Detailed Submission 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
The i-THRIVE programme aims to improve children and young people’s mental health outcomes by working with 30 sites across the country to implement the THRIVE framework.
Overview of Innovation:
i-THRIVE is national programme of innovation and improvement in child and adolescent mental health. It is an NHS Innovation Accelerator and is currently being implemented in national accelerator sites across the country. It is delivered by supporting localities to implement the THRIVE Framework through their CAMHS transformation and service improvement programmes.

i-THRIVE Community of Practice 
More than 30 sites make up the i-THRIVE Community of Practice. The Community of Practice includes organisations that are using the THRIVE framework as the basis of their CAMHS transformation and improvement programmes who then share learning about the implementation of THRIVE and how it can be adopted to fit with their local plans for service redesign. Nearly 25% of the young people in England live within a locality that is a member of the i-THRIVE Community of Practice.

THRIVE
THRIVE Elaborated (Wolpert et al, 2015) can be downloaded here: THRIVE Elaborated

i-THRIVE
i-THRIVE is the implementation of the THRIVE conceptual framework, translating the THRIVE core principles into models of care that fit local contexts. Key to this process is the use of evidence based approaches to implementation.
 
i-THRIVE supports the provision of services using a whole-system, or place-based, approach to the delivery of child mental health services. This involves taking a population approach to delivery of care; enabling integration across health, care, education and third sectors, and a central focus on delivering improved outcomes for children and young people.
 
Choice and personalisation of care are core values and these are delivered in part through systematic implementation of shared decision making. To support this, a range of validated measures, tools and educational programmes have been developed by partners and are included in the i-THRIVE Implementation Toolkit, including the CollaboRATE measure, Option Grids and shared decision making training through the i-THRIVE Academy.

i-THRIVE Partnership Organisations
i-THRIVE is delivered through a partnership between the Anna Freud National Centre for Children and Families, the Tavistock and Portman NHS Foundation Trust, the Dartmouth Centre for Healthcare Delivery Science and UCLPartners.

Further Information
Further information about i-THRIVE and examples of successful implementation in sites can be found at http://www.implementingthrive.org/. For the latest news and updates you can also follow us on Twitter: @iTHRIVEinfo.
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Innovation and adoption / Person centred care
Benefit to NHS:
i-THRIVE and the THRIVE framework have been developed to align with and to support established system transformation and quality improvement methodology. The i-THRIVE model is aligned to emerging tariff payments and is identified within Future in Mind as a suggested model of care.
 
i-THRIVE encapsulates many of the key strategic requirements for delivering CAMHS over the next few years. The NHS Five Year Forward View emphasises services being person-centered, the importance of early intervention, taking a whole system approach and enabling self-care, all of which are core to the THRIVE framework and in the delivery of i-THRIVE. By supporting sites to deliver i-THRIVE we will be helping them to deliver the changes called for in Future in Mind.

Expected benefits include increased proportion of young people accessing CAMHS with higher proportional improvement in vulnerable groups due to outreach and the location and accessibility of assessment services. There will be increased use of community services, self-care and peer-support networks as a result of effective signposting. We expect to see a reduction in waiting times and increased engagement with services with young people involved in co-designing services, their care and in peer-support networks. Efficiency gains are also expected.
Initial Review Rating
4.40 (2 ratings)
Benefit to WM population:
We are currently working with sites in the West Midlands to support them in the delivery of i-THRIVE.
Current and planned activity: 
i-THRIVE is currently supporting 30 sites across the country to develop and implement the THRIVE framework as part of their CAMHS transformation plans. The programme is funded by Health Education England, The Health Foundation and the NHS Innovation Accelerator to directly support NHS sites  and their partners in local government, education and the third sector, by providing learning and development resources, sharing evidence based tools for implementation, the sharing of good practice and support for evaluation.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
3
Read more
Hide details
Emma Louisy 06/09/2016 - 16:24 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Flo-Tone CR is a tool helping patients acquire good Maintenance & Technique in using Pressurised Inhalers, teaching how to Inhale SLOWLY and STEADILY. Inhaler Technique Skills are important and a major theme in BTS, GINA and NICE guidance.
Overview of Innovation:
Flo-Tone MDI (also known as Flo-Tone CR) uses a ‘Positive’ Coaching Whistle to help patients learn to inhale SLOWLY and STEADILY. Whistle Signal is a prompt for the canister to be pressed releasing the medication & the duration of the Whistle helps the professional to coach the patient towards correct use.
Pressurised inhaler mouthpieces come in a variety of shapes, accordingly Flo-Tone was originally produced in ‘Circular’ & ‘Regular’ Models. A new improved Flo-Tone CR now fits all mouthpiece shapes by fitting inside the pMDI mouthpiece. The new design ensures all pMDIs produce a whistle at the same flow rate, helping standardise technique.
Studies have been conducted with the new Flo-Tone to ensure that it delivers the full dose. The first study detailing the development of the improvement & its performance was presented at BTS 2015 & subsequently at DDL26.
Available on prescription, the improved Flo-Tone CR can be used with a pMDI simulator (Trainhaler) for training & with the Patient pMDI. It incorporates a cap so that it can be left in situ on the Inhaler. It also includes a rim on the mouthpiece to help patients get their teeth out of the way of the aerosol spray.
We have tested Flo-Tone CR with a variety of inhaled medications (Flutiform, Clenil, Ventolin, QVAR and Sirdupla) – in each case the respirable dose (ie that part that reaches the lungs) delivered for the medication plus Flo-Tone closely matched that of the device alone & in each case unwanted throat deposition was reduced.
•Flo-Tone CR controls the resistance of the pMDI, thereby standardising the flow rate at which  
  Flo-Tone CR whistles
•Provide inhalation & coordination guidance
•Sounds (20-25 L/min)
•Drug delivery improvement = Therapeutic Improvement
•Less throat deposition – potentially less unwanted Throat Side-Effects
•Better control - less breakthrough – less SABA needed
•Better control – less hospitalisation 


• Spacer & Mask with anti-Microbial & anti-static properties
Collapsible – helps with storage & travel
• Visible valve movement - see that the drug is being Inhaled
• Suitable for adults & children
• Performance validated with pMDI’s
• Accepts all pMDI’s available
• Available with small & medium mask


• Ideal for emergency services use, schools & within General Practice & Hospitals for reversibility testing
• Single patient use
• Economical & environmentally friendly
• Performance validated with pMDI’s
• Available in bulk pack 
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
There have been many papers published, detailing the misuse of pMDI among patients;
Clement Clarke International have used their expertise to concentrate on this area of products. This
has led to the introduction of the ‘Inhaler Technique Training’ range. Each device is targeted at the
training of inhalation technique, guiding patients to inhale at the correct flow rate for pMDI use.
 
Inhaler technique errors occur in the hands of patients and healthcare professionals. It has been
demonstrated that the majority of healthcare professionals cannot demonstrate correct inhaler use
to their patients. It is not therefore surprising that patients are mostly unable to demonstrate good
inhaler technique. The consequences are significant; patients take higher doses to compensate for
lack of efficacy from medication lost through poor technique, this results in poorer control,
hospitalisation and increased healthcare costs.

The Clement Clarke ‘Inhaler Technique Training’ range delivers more reliable, more effective and patient friendly usage of medication and treatment (therapy) delivery.
Benefits summary
  • Patient friendly medication management and use
  • More effective and accurate delivery of medication to lungs
  • Reduced number of hospital admissions
  • Reduced number of un-planned clinical interventions
  • Reduced associated therapeutic costs
  • Improved patients’ health and quality of life
  • Available on the National Drug Tariff
  • Low cost devices
  • Available for immediate use
Initial Review Rating
4.00 (2 ratings)
Benefit to WM population:
The West Midlands region provides a great opportunity for rapid realisation of the benefits of improved inhaler training from a clinical, economic and patients’ quality of life perspectives.

All the required products and training materials are currently available for instant deployment and would offer significant benefits to those GP practices or secondary care providers willing to challenge existing ineffective training and delivery mechanisms and who would act as either the Regional or National adoption lead.
 
A comprehensive breakdown of the tools and devices required for a GP practice has been provided in an attached document (Essential Requirements for GP Practice Inhaler Training Kits).
Current and planned activity: 
Current NHS activity
Key areas of Contact are Lung Function & Respiratory Medicine which include Respiratory Physiologists & Respiratory Nurses both in Adults & Paediatrics.
 
Flo-Tone has been adopted by Wolverhampton CCG.

Planned/required activity
As a Manufacturer, Clement Clarke undertakes an extensive R&D program and also undertakes On-Site Clinical Trials with GP Practice & Secondary Care.
However, research and trials support partners would be welcomed to further develop the evidence base demonstrating the benefits of improved staff training with associated patient benefits.
In addition, Health Economic studies would also be welcomed to quantify the medication and admission cost savings that would be achieved. This would supplement the Isle of Wight study and include a wider geographical and ethnic / demographic patient cohort.
What is the intellectual property status of your innovation?:
All intellectual Property for devices and training is held by Clement Clarke International
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
3
Read more
Hide details
Anthony Silvio Philips 31/08/2016 - 12:46 Publish Login or Register to post comments
4
1
Votes
-99999
Innovation 'Elevator Pitch':
Disruptive technology prevents Left Ventricular remodelling post MI & promotes tissue regeneration. Product result of £10M EU investment & 5 years R&D. Biocompatible & Biodegradable product demonstrated pre-clinically in wide range of animal model.
Overview of Innovation:
Cardiac patch is a scaffold structure compatible with in-vitro cell seeding & cell culture used as a vector for cellular therapy in addition to structural support. Numerous applications include curettage & cardiac transmural use in addition to soft tissue engineering such as hernias & vein repair. Scaffold composition comprises poly(caprolactone), alginate & composites thereof with natural polymers such as chitosan & alginate fibroin decorated with a synthetic peptidic hydrogel. Porosity can be tailored with pore range of 10-250µm, permitting angiogenesis and cell seeding. Although the biomaterial can be used independently as a medical device for prosthetic applications, its main tissue engineering function is to enhance cell attachment, growth & differentiation. An extension of the device is its functionalisation with cell signalling agent capacity providing the scaffold with extracellular matrix like micro-environment. Polymeric self-assembled structure is composed of but not limited to peptidic or polyurethane amphiphiles & can be loaded with chemical & biological cues covalently or via entrapment.

To initiate regeneration, the biomaterial must encourage in-vivo revascularisation & promote integration with host tissue. Concurrently, it should biodegrade at the same rate that newly formed tissue replaces it, being removed from the body by natural metabolic pathways without toxic by-products.

The patch provides both a temporary mechanical support to the infarcted myocardium preventing further damage to the surrounding tissue and prevents aneurism formation in the infarcted area whilst regeneration take place

Myocardial infarct treatment
Device can be used for in-vitro & in-vivo applications. Both parts of the device can be loaded with cell signalling agents or drugs for research & clinical use. Fibre based secondary drug delivery structure allows multiple growth factor/drug release with different release profiles as a direct tool for gel functionalisation with patient blood components in-vivo.

The system’s mechanical properties match the tissue it replaces. 3D hydrophobic/hydrophilic scaffold provides mechanical support to a gel that acts as scaffold plasticizer & provides an hydrophilic interface with host environment. The gel can also collect cell signalling agents from its immediate environment. The electrospun fibre based drug delivery system can additionally be used as a complementary tool to the gel for loading with cell signalling agents, drugs etc
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:
The leading global trend in interventional cardiology is to adopt less invasive technologies, reducing patient recovery time & improving quality of life.
 
PeptiGelDesign Cardiac Patch treats myocardial infarction (MI). Current treatments are based on medication &/or organ transplantation. Approx. 4,600 heart transplants are carried out pa in Europe & the USA (1,900 EU). Even with current medical management, over 1/3 of acute heart attacks are fatal. Rehabilitation levels following MI are variable with major damage unable to be fully healed. Current treatments to prevent tissue damage post MI include thrombolytic agents. These drugs have greatly reduced morbidity & mortality, but must be administered within a short interval following MI to be effective. Cardiac catheterization & Angioplasty have proven effective in restoring blood flow, but cannot reverse tissue damage. Transplantation is complicated surgery, severely limited by lack of donor organs.


Advantages of cardiac patch over current treatment regimes:
 
• Complements established therapies restoring damaged cardiac muscle ensuring improved contractility function & eliminating CHD related early mortality. Following non-lethal MI current treatments effectively restore blood flow, but cannot reverse tissue damage leading to limited rehabilitation & QoL
 
• Restoration of cardiac function drastically reduces re-infarction rates & need for subsequent interventions.


• Demonstrably increases life expectancy post MI. In cases of CABG (bypass), 5-year mortality rate for target population (patients with abnormal Left Ventricular (LV) function typically caused by MI) is 16.5% vs a mortality rate for patients with normal LV function of 8.5% (50% improvement). We could expect the cardiac patch to reduce mortality of patients undergoing MI to the level of those with normal LV function due to recovery of infarcted heart. Similarly, 5-year mortality rate of 80% for post MI patients undergoing an interventional procedure decreases to 40% - the mortality rate for patients undergoing the same procedure but with normal LV function.


• By enabling recovery of the heart muscle patients improve their NYHA class, suffer less Angina Pectoris, reduced incidence  of re-infarction, need less medication & hospitalization & improve QoL. NB: 10 years post CABG intervention, overall survival rate is 69% vs overall event free rate of 41%, suggesting that a significant portion of patients are surviving but with a fairly low QoL
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
In addition to the many benefits to the wider NHS outlined above, there are specific regional benefits accruing from the adoption of this medical device and treatment regime.
 
The high incidence of Chronic Heart Disease and the costly rehabilitation of patients post heart attack is a recognised priority within the West Midlands population.
 
The cardiac patch offers a minimally invasive and rapidly deployable intervention that will significantly improve the quality of life for patients surviving Myocardial Infarction.
 
In addition, the cost and time savings to the NHS and social care through improving patient outcomes, reduced number of transplants and greater quality of life and increased independence for patients post MI will be significant.
Current and planned activity: 
(See attached document for more information)
PeptiGelDesign is currently engaged with the Liverpool Heart and Chest Hospital.

Wish to partner with NHS and NHS Research Organisations on clinical trials for cardiac patch development.

As our primary target market is the UK, we wish to raise profile within the NHS and work with its stakeholders to bring our technology to the market and ultimately to the patient.
  • Explore if entitled to an  Investigational Device Exemption (IDE) ?
  • Identify sources of funding to support PeptiGelDesign pursuing the further validation.
  • Procurement/Adoption: -  Require routes to GP sales - marketing products to CCGs
  • Evaluation/Validation/Clinical Trial - Need to gain additional validation - seeking a trial centre.
  • Concept Development - This is planned development work but seeking NHS partnership/advice.
Project Assistance required - The Company is interested in locating clinical/academic collaborators for new product development.
What is the intellectual property status of your innovation?:
PeptiGelDesign Ltd is licencing the WO2014044321 and finance patent granting process. Today, the patent has been accepted in USA, EU and Japan and will enter EU countries national phase in December 2016.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Guillaume Saint-Pierre 04/08/2016 - 10:33 Publish 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Half a million adults and children in the UK experience severe asthma symptoms despite high dose medication. Air4 offers a non pharmacological treatment of allergic disease using Temperature Laminar Airflow to reduce exposure to allergens in the bed.
Overview of Innovation:
Air4 is a unique, innovative medical device which uses Temperture Laminar Airflow (TLA) technology to protect patients with severe allergic asthma and eczema, from exposure to allergens and other airborne particles (pollens, housedust mite and animal danders etc.) that are in and around the bed at night whilst they sleep. The device has no side effects and can therefore be used for adults and children.

Air4 is installed in the bedroom alongside the bed; air is drawn in the device from the room where it is filtered and cooled to 0.5-0.8 degrees centigrade lower than the ambient temperature. As cool air is heavier than room temperature, gravity ensures the air gradually descends without an excessive breeze or draught creating the patients breathing zone; due to the density of the air in the breathing zone airborne allergens are unable to penetrate and therefore the patient sleeps in an allergen free zone.

In reducing the airborne allergens the device has shown in clinical trials that is has reduced exacerbations and the number of hosptial admissions; it has reduced day and night time symptoms in patients and improved quality of life (health related) and has shown to reduce the number of days off work/school.

Air4 has a Medical Technology Innovation briefing from NICE stating the device is clinically and cost effective.There is also an Innovation Medical Technology Overview  from Helath Improve Scotland showing the device is clinically and cost effective compared to standard treatment.

Using the Air4 in adults or children who are still symptomatic despite maximum inhaler treatment; can avoid long term side effects from oral corticosteroids as well as the regular hospital visits from other treatmenst

 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Innovation and adoption / Person centred care
Benefit to NHS:
  • Reduction in exacerbations leading to fewer hospital admissions and clinic visits
  • Reduction in use of rescue medication leading to a reduction in drug spend
  • Reduction in the number of days taken off school and work
  • Cost effective and in some circumstances cost saving treatment. Annual rental cost is offset by the economc savings in medical costs resulting in a net cost to the NHS 
  • Fulfils Care closer to home: encouraging people to live independently; provide greater choice and control over health; Reduce NHS costs and the demands for hospital resources
Initial Review Rating
4.20 (2 ratings)
Benefit to WM population:
Home based overnight treatment which negates the need for hospital stays.
Improvement in quality of life (HRQLS)
Improvement in sleep
Reduction in the need for rescue medication
Reduction in exacerbations and therefore hospital stays and clinic visits.
Current and planned activity: 
Current Activity: Ongoing UK trial (LASER) with results due in spring 2017 (West Midlands have 2 investigator sites)
                          Working with Innovation Nexus Greater Manchester to support clinicians use of Air4
 Current Device Use: Royal Wolverhampton, Hereford
Planned Device Use: Birmingham Childrens, Sandwell, Worcester
What is the intellectual property status of your innovation?:
IP is held by the company
Current Certification: Class 1 Medical Device; CE Marked
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
Air4 is already being used in several accounts across the West Midlands with several more interested in trying the device. From a company perspective the warehouse will be informed of potential numbers and they will increase production to ensure they can meet with the increase in demand
Measures:
Overall measure of success of our innovation will be to see it accepted as a standard of care treatement for allergic disease and no longer applied for by an IFR for clinical exceptionality.
Quality Measures: Airsonett has implemented a quality management system compliant with ISO 9001, 13485 and QSR
Safety: Air4 is a CE marked class 1 medical device. As it is a non pharmacological device there are no known side effects and the device is installed,set up and removed by trained technicians.
Cost: There has been an economic analysis published in the BMJ Open Respiratory Research which found that the Air4 was a cost effective addition to standard treatment in patients with severe uncontrolled atopic asthma. These high risk patients with severe atopic asthma who use Air4 could reduce the incidence of hospitalization which could be cost saving to the NHS. Brazier et al (2015)         Airsonett® would be added to existing treatment and the average cost of long term treatment is £5.72 per day. Estimated cost of add on therapy currently used in the NHS is Omalizumab at approximately £23 per day.
The cost utility analysis estimated an incremental cost effectiveness ratio (ICER) of £8998 per quality of life adjusted year (QALY) with Airsonett®® compared to NHS standard care based on an incremental cost of £553 and a QALY gain of 0.0615. http://www.nice.org.uk/advice/MIB8/chapter/Technology-overview
People Measures:Success of the device will be measured using the following key performance indicators at 3 months for children and 6 months for adults: Improvement in the Asthma Control Test (ACT); reduction in exacerbations (compared to previous 12 months); reduction in or stopping of oral corticosteroids; Improvement in the Asthma Quality of Life Scores, adult and children (AQLQ: PAQLQ) and also improvement in sleep, work/school, and comorbid allergic disease such as eczema and/or perinnial rhinitis.
Adoption target:
Currently in WM there are 2 sites in the Laser trial (adult) and 2 sites (Paediatrics) who have patients on the device; approximately 5 additional sites across the WM with an interest. Based on the current interested sites I would estimate in the first year approximately 30 patients.
Read more
Hide details
Sarah Renshaw 03/08/2016 - 15:59 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
LiverMultiScan is an FDA 510(k) cleared and CE marked MRI technology that provides a quantitative assessment of liver health, including fibroinflammatory disease, steatosis and iron, all in a non-contrast 5 minute scan.
Overview of Innovation:
Perspectum Diagnostics is a medical imaging company with an ISO 13485 compliant CoreLab. The company has developed novel imaging technology, LiverMultiScan, an MRI-based non-invasive tool that has attained CE-marking and FDA 510(k) clearance to aid the diagnosis of patients with chronic liver disease.
LiverMultiScan (and LiverMultiScan Discover for clinical trial use) can characterise liver tissue in three ways, providing accurate measurements of liver fat, hepatic iron content and fibro-inflammatory disease, using the proprietary Liver Inflammation and Fibrosis (LIF) score. The LIF score has been shown to stratify NAFLD and NASH patients (Pavlides, 2015), correlate with histological markers of inflammation and fibrosis (Banerjee, 2014), and most importantly, is the first imaging test to predict liver-related clinical outcomes (Pavlides, 2016). It is the only liver imaging technology included in the UK Biobank study, with 100,000 scans to be performed in the coming years (Kelly, 2015).
Available as a Quantitative Analysis Service (QAS), LiverMultiScan has been cleared as an imaging tool to aid the diagnosis of early liver disease. It offers a standardised and high-quality method for supporting Gastroenterology/Hepatology and Radiology departments in diagnosis and monitoring of the liver in clinical settings and studies, and has potential to streamline clinical management by compressing the diagnostic pathway. Perspectum is also supporting multiple international clinical trials with LiverMultiScan Discover.
  • Banerjee et al. (2014) Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 60:69-77.
  • Kelly et al. (2015) Predicted prevalence of NAFLD and NASH in a large population using non-invasive multiparametric MRI. AASLD 2015. Abstract ID: 931.
  • Pavlides et al. (2015) Multi-parametric magnetic resonance can accurately assess NAFLD histological disease severity; comparison with transient elastography. AASLD 2015. Abstract ID: 2190.
  • Pavlides et al. (2016) Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol. 64:308-315.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wealth creation / Clinical trials and evidence / Digital health / Patient and medicines safety
Benefit to NHS:
The utility of LiverMultiScan for assessing fibroinflammatory disease, steatosis and predicting clinical outcomes means it is well-positioned to reduce (and potentially remove) the need to perform invasive liver biopsies. It also facilitates longitudinal monitoring, which is near impossible with current sampling technology.
According to a recent NIHR HTA report, the cost of a liver biopsy is £956, but this can increase significantly with complications (clinically significant bleeding in 1.1 – 1.6%). For healthcare providers, liver biopsies are unappealing because of the attendant risk, financial cost, lack of reliability (as sampling only 0.002% of the liver volume), and uncertainty in interpretation. Nevertheless, primarily because there has not been a viable alternative, it is estimated that 650,000 liver biopsies are performed annually worldwide. 
There are substantial costs associated with managing patients with NAFLD, in particular for those patients progressing to NASH who are at significant risk of cirrhosis, HCC and liver failure. Although pharmacologic options are limited, there are numerous clinical trials ongoing.
Available treatment options increase (e.g., diet, surgery), outcomes improve and healthcare costs decrease the earlier those with, or at risk of, more advanced disease are identified. When combined with the rising incidence of NAFLD and NASH, the availability of a non-invasive test for accurately assessing fibroinflammatory disease, steatosis and predicting clinical outcomes, is vital.
A recent health economic study (submitted for publication) from the University of Birmingham concluded that LiverMultiScan is cost effective either as an adjunct to or replacement of Fibroscan in the diagnostic pathway of NAFLD. In addition, the utility of LiverMultiScan in reducing the proportion of patients with suspected NAFLD undergoing hospital consultations and/or liver biopsies is currently being evaluated in a large Europe-wide multicentre clinical trial (including the UK).
LiverMultiScan could allow:
  • A faster throughput and diagnostic analysis than conventional sampling – reducing patient lists and identifying those that need and do not need clinical intervention.
  • Regular monitoring of patients without painful invasive and potentially dangerous biopsies.
  • A less traumatic assessment of liver disease in children.
  • Assessment of liver health in other diseases (e.g., viral hepatitis, alcoholic liver disease)
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
Liver disease is the fifth ‘big killer’ in England and Wales, after heart, cancer, stroke and respiratory disease (http://www.britishlivertrust.org.uk/about-us/media-centre/facts-about-liver-disease), with twice as many people dying from liver disease now compared to 1991.
In a European study, the healthcare costs for patients with NAFLD were 26% higher than for those without the disease (Baumeister, 2008). In the US, the direct costs of cirrhosis and chronic liver disease were estimated to by $2.5 billion, whereas indirect costs were estimated to be $10.6 billion (Ruhl, 2008).
Identifying those with, or at risk of, more advanced liver disease earlier increases treatment options available, reduces healthcare costs and improves outcomes. Benefitting both the NHS and wider West Midlands community.
This diagnostic test could also be used to aid the diagnosis and monitoring of liver disease in children, with a European clinical trial underway.
 
  • Baumeister et al. (2008) Impact of fatty liver disease on health care utilization and costs in a general population: A 5-year observation. Gastroenterology. 134:85.
  • Ruhl et al. (2008) Costs of digestive disease. In The Burden of Digestive Disease in the United States. NIH Publication. pp 137-143.
Current and planned activity: 
LiverMultiScan currently in use at University Hospitals in Birmingham, Edinburgh, Oxford Southampton & Kings College London (KCL). Discussions with other NHS sites

Recent completion of large Innovate UK funded 2.5 year study at University Hospitals Birmingham & Edinburgh to develop & validate against liver biopsy

KCL is UK site for large EU multi-centre clinical trial to evaluate cost-effectiveness of LiverMultiScan in primary care pathway.

Patient study - 100 patients with history of liver disease receive LiverMultiScan, nearing completion with extremely +ve feedback

LiverMultiScan is only liver imaging technology in UK Biobank - 100,000 subjects to be imaged

Planned activity
West Midlands location of choice as:
  • Build on relationship with University of Birmingham following 2.5 yr study
  • West Midland’s considerable expertise in liver disease
  • Large patient cohort and trials infrastructure
  • Involve Children’s Hospital in study
  • Dr Banerjee, founder & CEO, visiting Hon. Consultant Hepatologist at UHB
What is the intellectual property status of your innovation?:
Perspectum holds or exclusively licenses 7 patent applications in the UK and other territories. To date, one has been granted in the UK (GB2497668).
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Matt Kelly 03/08/2016 - 12:07 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':

We know that time in the NHS is precious, why waist time plugging in and charging devices when you can simply place the device on our stand. Don't lean over a tablet for lengthy periods; use our stand to alleviate posture issues, aches and pains.
Overview of Innovation:

Qlic is a Universal tablet stand with charging capabilities. Qlic has several models; cable suitable for both apple and android tablets, simply plug the charging cable into your device and plug the power supply unit to the wall. Our QI patch receiver can enable most devices for wireless charging. Insert the connecter to the charging point on your device, stick the patch to the rear and pop your tablet or phone back into its case (compatible with cases up to 5mm thick).

 Qlic was designed to save time for tablet users as well as to provide a more ergonomically suitable solution for people who use mobile devices on a daily basis.

​We believe that as mobile devices become more and more popular within care settings Qlic will help to support the working environment within NHS trusts.

​Qlic was originally developed to support the learning environment within schools and has proven to be very popular within educational settings (please see our product video - https://www.youtube.com/watch?v=Cepvxf07oU8).

After looking into the NHS and the use of mobile devices we thought that Qlic would be ideal for NHS settings as well. Not only will Qlic save time and effort, you won't need to think about charging the device as simply placing the device on the cradle will enable charging to begin. We looked at the use of mobile devices and thought that our stand would be ideal on nurses stations, for use by clinical leads, office staff, ambulances and drug trolleys as our stand can also be permanently fixed to surfaces. 

​We would like to find out the type of tablets/ mobile devices and the type of protective cases currently used to ensure that our stand is suitable for all. We would also like suggestions on where you think our product would be most suitable for use? Where would Qlic make your life easier?  



 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Digital health
Benefit to NHS:
  • Time and space saving.
  • Easier to view content on mobile devices.
  • Secure.
  • Enables the user to sit in the correct ergonomic position.
  • Ensures mobile devices are charged at all times.
  • Ensures mobile devices are easily accessible to users.
Initial Review Rating
2.80 (2 ratings)
Benefit to WM population:
Qlic will improve efficiency in the NHS settings within the west midlands by ensuring all mobile devices are fully charged at all times. Qlic will ensure that Staff will have one less thing to worry about with regards to daily use of mobile devices enabling more time spent on more important tasks and with patients. 
Current and planned activity: 
We are not currently involved with the NHS but are willing to undertake any developments needed.
What is the intellectual property status of your innovation?:
Patent pending on the cardle adjustment. The design is a registered design with the government IPO.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Katie Loforte 01/08/2016 - 12:43 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
The National Osteoporosis Society has pioneered a package of support for the commissioning and improvement of secondary fracture prevention services.  This can save the average CCG 1.7m over 5 years.
 
Overview of Innovation:
The Fracture Liaison Service (FLS) care model enables secondary fracture prevention through identification of low trauma or fragility fractures by means of dedicated case finding, with assessment and treatment of osteoporosis where appropriate.  This model has been replicated across the UK since April 2015 with the support and expertise of the National Osteoporosis Society.  A team of specialist development managers with clinical and commissioning experience is currently working with 167 sites (to date) to support new service development (50), or quality improvement of existing services (78).  Preliminary results from an analysis of the effectiveness of these services in preventing secondary fractures indicate a significant positive difference between sites with an FLS, and those without.

Operating in a tough economic climate with health budgets tightly constrained, investment in new services must demonstrate both a solid evidence-base and a strong business case.  There is strong evidence that investment in FLS results in improved quality of care and financial savings in health and social care.  The NOS has produced a suite of online resources to support FLS development and improvement.  A comprehensive FLS Implementation Toolkit supports providers and payers in the commissioning process and is provided free of charge. [1] Users can create a compelling, evidence based business case without the need for advanced skills in costing, modelling or other health economic techniques.  The SDT is also available at any stage throughout the implementation process to support clinical pathway or business case development.  Advice is available regarding outcome measures and performance indicators, as well as effective data collection for service evaluation.  This service is provided free of charge. 

To date, 9 new FLS have been commissioned (8 new services and 1 augmented service).  These new services represent FLS provision to an additional cumulative population of nearly three million people, which could prevent more than 1000 hip fractures over 5 years.  This in turn represents gross savings across health, social care, and community services of £17.3m (service costs typically run at less than 40% of the gross benefit).
 
[1] The Implementation Toolkit https://www.nos.org.uk/health-professionals
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Innovation and adoption / Person centred care
Benefit to NHS:
The aim of the National Osteoporosis Society (NOS) is a future without fragility fractures.   Fragility fractures are common: 1 in 2 women and 1 in 5 men break a bone after the age of 50.[i]  People who have had one fracture are at greater risk of sustaining another (i.e. a secondary fracture).  There is strong evidence that investment in Fracture Liaison Services (FLS) results in improved quality of care and financial savings for the whole associated health economy.  
As highlighted earlier, to date, nine new FLS have been commissioned nationally (eight new services and one augmented service), with the support of NOS project management.  These new services represent FLS provision to an additional cumulative population of nearly three million people, which could prevent more than 1000 hip fractures over five years.  This in turn represents gross savings across health, social care, and community services of £17.3m (service costs typically run at less than 40% of the gross benefit).
 
[i] Van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales, Bone 2001; 29 (6):517-522.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
As part of the FLS Implementation Toolkit[i], the NOS has developed a financial model (the FLS Benefits Calculator) which demonstrates potential future fracture reduction and cost savings for any given population.  Taking an exemplar from the West Midlands: If Coventry and Rugby CCG were to commission a FLS, the Benefits Calculator indicates that 345 fractures would be prevented over 5 years of operation of the service.  Of these, 145 are hip fractures, which at a conservative estimate, cost the health economy around £17,000 each.  
The calculation shows a total gross saving[ii] of £2,909,841 - £1,470,702 in acute care, £1,362,565 in social care and £76,574 in community and primary care.
 
[ii] We estimate the cost of the service to be approximately 37% of the gross benefit
Current and planned activity: 
The NOS is currently providing bespoke project management support to 168 sites across the UK, including 15 sites in the West Midlands area, looking to set up or improve an FLS:  
  1. Facilitation of engagement with stakeholders to generate commitment to FLS.
  2. Assistance to stakeholders from inception to launch of FLS, including development of the economic and business case; service specification; and resource and capacity planning.
  3. Assistance with recruitment and training of the fracture liaison nurse (FLN). [i]
  4. Input to enable the development of an FLS to meet the UK FLS Clinical Standards. [ii]
  5. Help to establish relevant protocols/care pathways for the service.
  6. Work with commissioners to ensure services are sustained.
  7. Assistance re. data collection and methods of analysis, reporting and evaluation.
 
[i] FLS Fracture Prevention Practitioner Training https://www.nos.org.uk/health-professionals/elearning
What is the intellectual property status of your innovation?:
The Implementation Toolkit is the property of the National Osteoporosis Society, but is available free of charge.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Read more
Hide details
Will Carr 04/07/2016 - 12:52 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
We run a Suicide Crisis Centre in Gloucestershire, which was set up and is run by a person with lived experience. We've been providing services for 3 years and have never had a suicide of a client under our care.
Overview of Innovation:
The charity Suicide Crisis was set up in December 2012. It was set up by a woman who experienced suicidal crisis following a traumatic experience in March of that year. She couldn't find the right kind of help so she created what would have helped her. Our services have evolved to become what our clients have said they want and need. They have shown us what additional services we have needed to provide.

First we set up a Trauma Centre in May 2013 and this continues to run as part of our charity. This is about early intervention: supporting people to try to prevent a descent into crisis. After she was discharged by the NHS crisis team in the summer of 2012, the founder of Suicide Crisis was told that there would be an 8-month wait before she could access psychological therapy. Whilst waiting for therapy, she attempted suicide twice. This highlighted the need for ongoing support after a traumatic experience.    

The Suicide Crisis Centre opened in autumn 2013 and is based in the centre of Cheltenham and serves the whole of Gloucestershire. Clients can come in every day when at high risk. We provide face to face individual support.

A client at particularly high risk will have access to 24-hour support.

We have never had a suicide of a client under our care and have identified a number of reasons why. We believe that it's because of a combination of the way that our services are set up and our ethos. We're happy to give presentations about our work to explain this.

We often look to psychiatrists and professors for possible ways of reducing the number of people who die by suicide. We are different in that it is a 'mental health patient' who came up with the idea of our Suicide Crisis Centre, set it up and who continues to run it. Although she had no contact with mental health services prior to 2012, she has since been diagnosed with bipolar disorder and a posttraumatic syndrome. We have gone beyond co-production. This has been originated by a service user.

Our work is now starting to attract national attention. We have been visited by Helen Garnham, the national lead on suicide prevention at Public Health England. She has described our work as "inspiring" and asked us to address a suicide summit in February in London. Luciana Berger, the former Shadow Minister for Mental Health, asked to visit us in January and met staff and clients. The South West Zero Suicide Collaborative's steering group has described our work as "inspirational" and "extraordinary". 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Wellness and prevention of illness
Benefit to NHS:
We are providing something very different from NHS services but have found that mental health professionals are interested in understanding why our clients survive and how we have achieved zero suicide.
Initial Review Rating
3.40 (2 ratings)
Benefit to WM population:
Our Suicide Crisis Centre is helping people to survive who may have died by suicide. We are also helping to prevent crisis by providing trauma services (early intervention).
Current and planned activity: 
We have been contacted by the NHS and CCG in another part of the country as they are interested in having a Suicide Crisis Centre in their county. This is outside the West Midlands.
What is the intellectual property status of your innovation?:
To be confirmed
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
3
Read more
Hide details
Joy Hibbins 01/07/2016 - 08:39 Publish 1 comment
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Bac-Track MicrobeCare reduce outbreaks of communicable infection control incidents, bed stays caused by Healthcare Associated Infections & costs associated with Primary/Secondary care outbreaks, facilitating compliance with CQC guidelines & EPIC 3
Overview of Innovation:
Test: In a room or facility undergoing the treatment programme, nominated locations recognised for high propensity to retain bacteria are tested using Adenosine Triphosphate (ATP). All nominated locations are given a unique code & the readings are uploaded onto the Bac-Track™ Dashboard.
 
Treat: The nominated rooms are then treated with MicrobeCare™ using an electrostatic sprayer, which unlike mist sprayers, negatively charge the particles to ensure uniform coverage across all surfaces. The advanced formulation of MicrobeCare™ has a very short (3-minute) dwell time to ensure swift decontamination is undertaken & its unique residual killing power, delivers a continuous long term antimicrobial & antibacterial surface protection killing bacteria for a minimum of 1 year.
 
MicrobeCare™
  • is an odourless, colourless, non-leaching, long lasting antimicrobial & delivers a permanently bonded antimicrobial barrier
  • kills bacteria, viruses, fungi, algae & yeast without dissipation 
  • permanently bonds to all surfaces, protecting them against further microbial contamination
  • does not wash off the surface it is applied to
  • does NOT allow for the adaptation into superbugs
  • does NOT transfer into the environment
  • clinically tested & EPA* approved. *United States Environmental Protection Agency (EPA)
  • is not designed to replace current cleaning protocols. By treating surfaces with MicrobeCare™ bacteria & virus levels will dramatically decrease & remain so for a minimum of 1 year following treatment. This could significantly reduce the potential for cross contamination & healthcare acquired infections (HAI) stemming from contaminated surfaces
Track: Bac-Track™ dashboard provides accurate data of a clinical facility & the equipment therein, monitoring comparative ATP results on an ongoing basis. This provides a unique, simple & affordable way to track contamination levels within a facility & reduce HAIs’. Bac-Track™ provides access 24/7 to monitor bacteria levels, monthly trends & cleaning effectiveness.
With this valuable information the user is able to pinpoint where the highest risk areas are for contamination & keep track of changes in the location of equipment. Bac-Tag also allows facilities to track bacteria & maintenance levels on their equipment. This tag is linked to the Bac-Track system enabling the user to see history, including treatment/maintenance schedules.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness
Benefit to NHS:
By incorporating Bac-Track and MicrobeCare™ your NHS Trust will benefit from:
  • a reduction in Healthcare Acquired Infections
  • a reduction in fatalities from Healthcare Acquired Infections, currently levels of over 5000 patient deaths per year that are preventable
  • a reduction in the amount of extended bed stays
  • a reduction in ward closures
  • a reduction in overall costs including: the cost of anti-biotics, cost of isolation, reduced bed occupancy, reduced blood stream infections, reduced disinfection cleaning costs, fewer staff hours lost through illness, fewer wards closures as a result of wide spread viral infection
  • Reputation of hospital or facility improves as no cases of virus reported
 
By using Bac-Track the NHS will benefit from the ability to monitor:
  • bacteria levels by department, equipment category and individual items
  • and identify trends, treatment and cleaning effectiveness
  • and pinpoint where the highest risk contamination areas
  • keep track of changes in the location of equipment
  • historical data by department or equipment category  
  • monitor the effectiveness and progress of Infection prevention protocols
​The cost of a HAI Outbreak such as Norovirus can be considerable and include:
  • Decontamination and deep cleaning
  • Additional care and treatment of effected patients
  • Staff Sickness and additional nursing costs to cover staff absence
  • Lost revenue through closures or restrictions
  • CQC compliance
  • Reputation damage
Results from our US Partners indicate, treatment programme costs are quickly recuperated through the reduction of HAI Outbreaks   
 
Initial Review Rating
3.80 (1 ratings)
Benefit to WM population:
Region wide benefit in the reduction contracted cases of viral diseases contracted within healthcare facilities ultimately resulting in fewer deaths. This would help to paint a regional picture of the quality of care in the West Midlands.
 
By incorporating Bac-Track and MicrobeCare™ the West Midlands region will benefit from:
  • a reduction in Healthcare Acquired Infections
  • a reduction in fatalities from Healthcare Acquired Infections, currently levels of over 5000 patient deaths per year that are preventable
  • a reduction in the amount of extended bed stays
  • a reduction in ward closures
  • a reduction in overall costs including: the cost of anti-biotics, cost of isolation, reduced bed occupancy, reduced blood stream infections, reduced disinfection cleaning costs, fewer staff hours lost through illness, fewer wards closures as a result of wide spread viral infection
  • Reputation of hospital or facility improves as no cases of virus reported
 
By using Bac-Track the West Midlands will benefit from the ability to monitor:
  • bacteria levels by department, equipment category and individual items
  • and identify trends, treatment and cleaning effectiveness
  • and pinpoint where the highest risk contamination areas
  • keep track of changes in the location of equipment
  • historical data by department or equipment category 
  • monitor the effectiveness and progress of Infection prevention protocols
Current and planned activity: 
Clinical Support Surfaces is not currently supplying to the NHS on any of our products. We work closely with our partner companies in United States where MicrobeCare™ has been tested and adopted and Australia who are currently launching Bac-Track™ and MicrobeCare™. We are actively seeking support and adoption of MicrobeCare™ across all NHS Trusts to establish the product within the UK market.
 
In the US a wide number of Healthcare facilities and Schools treated with MicrobeCare™ are successfully using Bac-Track™ to monitor monthly trends and treatment or cleaning effectiveness by department or equipment category demonstrating significant reductions in bacteria levels as well as virtually eradicating occurrences of HAIs’. A number of case studies are readily available.
 
Planned activity:
  • Procurement / Adoption of MicrobeCare™ across the West Midlands NHS Trusts
  • Support to get MicrobeCare™ into acute and community settings to ensure we get UK evaluation and endorsement
What is the intellectual property status of your innovation?:
Patents held for MicrobeCare™
 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
3
Read more
Hide details
Ian Bickerton 18/04/2016 - 12:15 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Birmingham Surgeons created endoscope-i an award-winning system that enables the viewing, recording & sharing of HD endoscopic images & videos using an iPhone/iPod. Endoscope-i works with existing endoscopes or supplied as a secured turn-key solution
Overview of Innovation:
Smartphones & tablets are becoming a central technology within clinical care systems for their high definition cameras, brilliant screens, integrated sensors and unlimited software potential.
 
Originally developed as a simple and cost effective solution to mobile endoscopic HD imaging Endoscope-i can benefit both clinicians and patients across several specialities. To date otolaryngologists, urologists, gynaecologists, orthopaedic physicians, laparoscopic surgeons and anaesthetists are some of the many specialties which benefit from using endoscopes. The superior lighting and optics allow for visualisation of 'hard to reach' areas within the human body. Endoscope-i has been involved in a number of projects globally to facilitate cost effective HD imaging and documentation.
 
The multiple award winning Endoscope-i is simple to operate and comprises an adapter to connect a medical endoscope to align with the camera of an iOS device (iPhone or iPod). The ‘e-iPro’ app allows the user to calibrate and centre the acquired image and prevents rotation allowing images to be recorded in high definition (HD) video or still images which can be shown to the patients and stored in the patient’s medical record in seconds.
 
Endoscope-i will fit any endoscope with a 32mm eyepiece, which means the possibilities are endless. A shared endoscopic view was previously the reserve of the privileged few   - where they have large expensive stacking systems - Endoscope-i makes this technology available to everyone, at a fraction of the cost and in a more convenient portable format.” 
People are surprised to hear that before Endoscope-i, clinicians relied on hand drawn sketches to update patient records.
 
NB: Data and images are currently distributed via NHS.net. Discussions are ongoing with the Information Commissioners Office to design bespoke data management protocols.
 
Endoscope-i is available to fit a range of iOS devices and has a multitude of uses which include both clinical and non clinical applications such as:-
 
Otolaryngology
HD imaging of the ear nose & throat to allow rapid and easy storage and sharing of images and videos with both patients and clinicians
 
Anaesthetics
Portable HD viewing to facilitate endoscopic fibre optic intubations available at any time
 
Veterinary
Small and large animal endoscopy from the surgery to the field using the most advanced portable camera technology
 
Engineering
Carry only one portable device for communication and sharing of images obtained on site
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
A target has been set for the NHS to become paperless by 2020. Many health trusts have facilitated this by creating their own electronic health record (EHR). However, though a transcription of the patient consultation can be typed directly into the record there is no efficient means of capturing and storing images of patient findings safely into the patient record.
 
The speciality of ear, nose and throat (ENT) examines areas of the body that are usually difficult to visualise without endoscopes. However even though there it is possible to see inside the ear nose and throat many doctors must then create a sketch of their observations for documentation.
 
To overcome this major problem, a mobile imaging solution - Endoscope-i - has been developed by a team of specialists which include engineers, software developers and practicing clinicians. The ‘Endoscope-i system’ uses the power of smart phones to quickly and safely capture images from endoscopes and store them directly into the patients EHR with the touch of a button. What’s more, patients can now share their own examination findings with their doctor or relatives to understand their condition better.
 
The images produced are of such high definition that they can be taken by doctors in primary care and then sent on to specialists in secondary care for an expert opinion, without the patient ever having to go to hospital. This saves the cost of an outpatient referral for the commissioning group, is far more convenient for the patient, reduces unnecessary journeys, frees Consultants’ clinic time, speeds diagnosis and in the long term could save millions of pounds for the NHS.
 
Initial Review Rating
3.27 (3 ratings)
Benefit to WM population:
The proposed ‘Telescopic Mobile referral service’ will allow patients to get expert opinions of their ear conditions within hours and without ever having to visit the hospital, thus saving valuable consultant time and minimising travel and inconvenience for the patient.
 
Reduced cost and greater access to services will result through the use of Endoscope-i as there is no longer a need for multiple data capture and processing devices as each Consultant can use their own iOS device to record and transfer images. Additionally, Endoscope-i will work with existing endoscopes that have a 32mm diameter eyepiece and so directly enhances the equipment’s clinical benefit.
 
In the three months of the Telescopic Referrals (Telemedicine using Endoscope-i) in North Staffordshire and Stoke and Trent, 27 referrals have been dealt with remotely from 6 GP practices. 24 of these cases were managed without referral giving an 88% success rate to referral.
 
In the West Midlands region, a new patient referral currently costs the CCG £107 compared to the remote ‘Telescopic’ referral cost of £30, a dramatic saving for the CCG. This has already saved £1,758 in referral costs alone without measuring the indirect cost benefits for patients who did not require the Telescopic referral because of the improved diagnostic ability the GP had when using Endoscope-i.
 
Reducing the need for a physical consultation will also result in transport savings and time ‘away from work’ costs for both the patient and any employer.
Current and planned activity: 
Current WMHASN funded project with Dr Ruth Chambers (Clinical Telehealth Lead at NHS Stoke-on-Trent Clinical Commissioning Group), using 15 practices from the S-O-T and North Staffordshire CCGs piloting the Telescopic Mobile Referral Service. Currently 3 months into preliminary data collection showing 30 referrals handled with Telescopic referrals powered by Endoscope-I technology. Almost 90% of patients referred avoid being sent to hospital. Cost of teleconsultation is only £30 compared to £107 for a new patient hospital consultation.
 
Endoscope-i not only provides a rapid consultant opinion for the patient but helps to deal with the excessive burden on secondary care services by keeping chronic disease and some acute ear disease management within primary care.
What is the intellectual property status of your innovation?:
No patent on product. We have full copyright of the code written for the app. Endoscope-i is a registered trademark and adapter designs fall under design copyright.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
Ajith George 13/04/2016 - 07:57 Publish 5 comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
The PCAF service is a nationally recognised, peer reviewed, multi-award winning service that is provided within GP practices to support the identification, diagnosis and treatment for patients with AF with the aim of preventing AF-related strokes.  
Overview of Innovation:
The PCAF service is an innovative consultant-led service that provides dedicated expert resource to GP practices to: 
  • Identify additional 'unknown' AF patients within the clinical system; 
  • Qualify the accuracy of the AF register(s), referring patients for diagnostics to secure a diagnosis where required;
  • Assess the risk of stroke within the AF population by using a robust risk assessment tool (i.e. CHA2DS2- VASc);
  • Undertake comprehensive case note reviews of all patients who have been assessed as being at high risk of stroke with the aim of identifying those who would benefit from receiving an expert review;
  • Provide ‘in-house’ consultant-led AF clinics, ensuring that all patients at high risk of stroke receive access to an expert review and patient education;
  • Optimise the treatment and management of patients with AF, supporting quality outcomes and an increase in health related quality of life;
  • Provide one-to-one and group clinical education, thus ensuring a ‘legacy’ is left amongst clinical teams within primary care;
  • Enable access to an AF Stroke Prevention RCGP and CPD accredited eLearning package, enabling clinicians to increase their knowledge and skills on the current evidence base;
Primarily, the service will optimise the treatment and management for patients with AF (whilst being fully compliant with NICE Guidelines, local guidelines/pathways and the local medicines management formularies), ensuring a reduction of AF related stroke incidence within GP practices.

The service comprises of the following four phases, all of which are provided by Inspira Health:
  • Phase 1 - PRIMIS audits are run on the practice clinical system (including GRASP-AF).
  • Phase 2 - 5 clinical audits are completed and involve comprehensive patient case note reviews.  Each audit will identify patients at high risk of stroke who would benefit from an expert review;
  • Phase 3 - Patients are systematically invited to an expert review and are provided with education;
  • Phase 4 - Patients are reviewed by an independent local specialist (e.g. Consultant Cardiologist) within their GP practice and their management is optimised.
All clinicians within the practice are provided with an opportunity for one-to-one education during Phases 2 and 4.  In addition, all clinical staff are offered the opportunity to undertake an RCGP and CPD approved AF Stroke Prevention on-line eLearning package which consists of 5 modules and a competency assessment through patient case scenarios. 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
The following are benefits to a GP Practice:

The PCAF servicve will ...
  • Identify 'new' AF patients through a case finding exercise on the clinical system;
  • Significantly improve the quality of the AF disease register;
  • Achieve maximum indicators and performance thresholds in 2016-17 QOF (as a minimum standard);
  • Increase capacity within the clinical team through increasing knowledge, awareness and confidence in relation to evidence-based treatment strategies for AF.  This is achieved through one-to-one education, group education and/or eLearning;
  • Increase anticoagulation therapy in patients with AF at high risk of AF-related stroke;
  • Reduce the incidence of AF-related stroke within the practice population;
  • Ensure compliance with CQC standards in relation to patient safety and clinical effectivness;
  • Independently review the practices current poathways, processes and governance in relation to warfarin patient safety;
  • Provide a unique opportunity for personal development (PDP) and to gain CPD points for appraisal and/or revalidation.
Implementing the PCAF service would mean allignment with a number of key themes and strategic objectives as per the commissioning plans across the West Midlands.  The service woiuld contribute towards the following:
  • Improved health and healthcare through the introduction of a high quality, outcome driven, innovative service;
  • Increased life expectancy and the quality of life in the local population through optimising evidence-based treatment strategies, therefore reducing AF-related stroke incidence;
  • Increased medium-long term efficiency and productivity through the introduction of a sustainable service and a more educated, confident primary care workforce;
  • Improved and accurate AF disease registers;
  • A reduction in CVD related mortality;
  • A reduction in unplanned hospital admissions;
  • Improved patient experience;
  • Value for money;
  • The introduction of evidence-based practice across the West Midlands footprint.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
The following are benefits to AF patients within the West Midlands

The PCAF servicve will ...
  • Increased a patients knowledge and awareness about their AF condition and their current and future risk of stroke through one-to-one education;
  • Provide an opportunity for patients to discuss their AF condition with a local expert within their GP practice;
  • Provide an opportunity for patients to learn more about their treatment options in relation to their overall AF management, quality of life and reducing their AF-related stroke risk. 
Current and planned activity: 
The PCAF service has been delivered in a vast number of GP practices and CCG's throughout the UK and has been recognised as a method of best practice nationally.

Inspira Health have engaged with the following key stakeholders;

CCG's
GP Practices
GP Federations
AHSN's
Public Health England
Public Health Departments
Strategic Clinical Networks
Pharmacutical Industry
Charity Sector (eg British Heart Foundation, Arrhythmia Alliance, Stroke Association)
Commercial Partners (eg, INR Star, Blue Stream Acadamy)
 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Commercial information:

The PCAF service is in full development and has been implemented in practices throughout the UK.

Read more
Hide details
Jennifer Mills 12/04/2016 - 14:20 Publish Login or Register to post comments
5.5
2
Votes
-99999
Innovation 'Elevator Pitch':
There is a growing understanding of the importance of patient safety in primary care. In response a Patient Safety Toolkit has been developed that consists of a total of eight tools that address patient safety across a number of domains.
Overview of Innovation:
The Patient Safety  Toolkit was a multi-site multi-phase venture funded by the NIHR National School of Primary Care Research. Tools were piloted across some 50 practices across England and were intended to meet the challenge of dealing with patient safety incidents across a number  of domains. The toolkit included an aid to rapid retrospective note review to detect patient safety incidents; an on-line survey to assess the safety climate amongst staff; a questionnaire to gauge patients’ experiences of safety in primary care; a software based intervention to prevent medication related injury; a tool to assess medicine reconciliation for recently discharged patients and a concise safe systems checklist .

The toolkit was the National School for Primary Care Research has said that the Toolkit project was one of the ten most valuable they have been involved in over the last decade. Each of the individual elements of the toolkit are available to download free of charge from the RCGP website (www.RCGP.org.uk) (http://www.rcgp.org.uk/clinical-and-research/toolkits/patient-safety.aspx)
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Education, training and future workforce / Patient and medicines safety
Benefit to NHS:
This is the first toolkit that has attempted to collate a series of tools designed to improve patient safety in primary care across a number of domains. 
Initial Review Rating
2.60 (1 ratings)
Benefit to WM population:
The toolkit is free to use, readily available and can help practices improve patient safety across a number of domains.
Current and planned activity: 
We have recently completed a number of workshops conducted across England to raise awareness of the toolkit. We will continue to promote and support its use through the use of forums such as the  Academic Health Science Network events. 
What is the intellectual property status of your innovation?:
This belongs to the NIHR.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Ian Litchfield 30/03/2016 - 17:20 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Combining patient demand, workforce availability & skills to deliver care, eCommunity supports right skill, right place, right time in the community, identifies daily & broader skill mix gaps, reducing time & improves quality of visit allocations
Overview of Innovation:
District and community nursing have unique pressures in terms of identifying and coping with high demand across a wide range of care needs. Service demand, rosters and skills have traditionally been held in separate systems, many of which are paper based. Bringing all this information together into a single visual solution enables service managers to make faster, smarter decisions ensuring quality care is delivered and the workforce isn’t burned out.
 
The additional released administration time for senior team members enables faster visit allocation and allows them to spend more time supporting their staff and patients.
 
eCommunity is a web based solution www.qes-online.com that enables visit allocators to rapidly plan days for frontline staff in under 30 mins, something that currently takes 2hrs +. This new allocation process is supported by supplying recommended best fit treatment by continuity, acuity, skills availability and location.
 
For the first time a team or whole service has a forward facing view of capacity and can create a roster to meet demand, be well informed of capacity gaps and proactively even out demand rather than react to circumstances.
 
Utilising a “care catalogue” dictating time and skill needed to deliver treatments, eCommunity ensures that the workload given to a member of staff is both appropriate for their skill mix and can be delivered within the allotted shift time, two advantages other services cannot evidence. “Actualising” the actual time it takes to deliver care and updating the care catalogue is a vital to ensure capacity and demand is based on real life evidence.
 
eCommunity is web based, making it accessible from home enabling staff to be well prepared for their first visit the following day, removing the need to “go to base” at the start of a shift saving hundreds of care hours a day.
 
Utilising smart capacity, demand & caseload allocations means fewer people can manage greater demand and larger teams. This further frees up often highly skilled team managers to focus on delivering care and supporting frontline staff.

eCommunity is the first dedicated operational tool designed by experienced, practicing community nursing teams to improve both the care delivery and working practices for staff.  This level of dynamic, real life operational support and intelligence has not previously been possible using existing clinical tools and systems.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Patient and medicines safety / Person centred care
Benefit to NHS:
The quality of care delivered will be significantly improved via the “care catalogue” that ensures that the nurses assigned to deliver treatments have the appropriate skills. This not only improves care quality but also improves job satisfaction and role engagement as staff know the scope of care is within their capacity.
 
One of the largest efficiency savings will be the releasing of time available to care. This is possible by pre-planning, enabling care delivery to commence immediately at the start of a shift, not requiring a pre-meeting at which the visits are allocated. Hundreds of hours of additional care time will now be made available.
 
Business intelligence is key to optimising available capacity and demand, identifying skills gaps and aiding training & recruitment. Team differences in care delivery are identified through visit ‘actualisations’ and an accurate picture of what treatments are being delivered. This smart business intelligence can be used to drive discussions with commissioning organisations.
 
Significant reductions in travel mileage will also be realised by ensuring smart navigation and scheduling of visits that optimise travel. Given the huge mileage covered in delivering care, even a small saving in distance travelled delivers big financial and carbon footprint savings.

eCommunity can deliver these advantages for large teams or small teams delivering specialised services via a single license for unlimited use.
Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:
eCommunity is flexible and adaptable able to work effectively with any kind of mobile workforce that includes a variety of skill mixes and challenges, where capacity and demand are under pressure.

Although primarily designed for use in community and district nursing, its value would be realised across any health or care service.
Current and planned activity: 
eCommunity now 12 months old and benefits in use are being collated
(See attached Appendix ‘Testimonials’ for NHS user testimonials)

eCommunity solutions have been trialled and liked by frontline staff and team leads. However, many care providers struggle to formulate suitable business plans to support investment, despite obvious savings, lacking adequate baseline data and IT support to evidence impact.
 
eCommunity development is ongoing to enable a ‘live view’ of workloads for all staff delivering care and flag when visits need re-allocation to ensure assigned visits & tasks can be delivered. This development is only possible by effecting cultural change to complete information immediately at the end of each visit, not waiting until return to base.
 
Work ongoing to integrate eCommunity within a clinical tool. Current tools are mis-perceived as the “be all and end all” of IT solutions by both frontline staff and senior management, despite their lack of support for operational needs
What is the intellectual property status of your innovation?:
IP is fully owned by QES
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Nick Chinn 23/03/2016 - 09:49 Publish Login or Register to post comments
4.3
3
Votes
-99999

Recent Activities

The Trans-Urethral Catheterisation (TUC) Safety Valve has been moved from Initial Submission to Publish 4 hours 33 min ago
PREP SHIELD - limb drape for the operating theatre has been moved from Initial Submission to Publish 3 days 9 hours ago
BUDDY® re-usable waterproof limb covers has been moved from Initial Submission to Publish 3 days 9 hours ago
Tide - Together In Dementia Everyday has been moved from Initial Submission to Publish 3 days 10 hours ago
Knowing Me! has been moved from Initial Submission to Publish 1 week 5 days ago

Active Campaigns